vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v16i4.1781vsp-1794Research ArticleИНФОРМАЦИЯ ОТ ФАРМАЦЕВТИЧЕСКОЙ КОМПАНИИINFORMATION OF A PHARMACEUTICAL COMPANYДИАГНОСТИЧЕСКАЯ ЦЕННОСТЬ ОПРЕДЕЛЕНИЯ УРОВНЯ ПРОКАЛЬЦИТОНИНА В ПРАКТИКЕ ИНФЕКЦИОНИСТАDIAGNOSTIC VALUE OF DETERMINING THE LEVEL OF PROCALCITONIN IN THE PRACTICE OF AN INFECTIOUS DISEASE SPECIALISThttps://orcid.org/0000-0003-4655-3375ПоляковаА. С.PolyakovaAnastasia S.

Полякова Анастасия Сергеевна - кандидат медицинских наук, врач-педиатр отделения диагностики и восстановительного лечения НМИЦ здоровья детей, доцент кафедры факультетской педиатрии РНИМУ им. Н.И. Пирогова.

Москва, Ломоносовский пр-т, д. 2, стр. 1, тел.: +7 (495) 967-14-21

Moscow

darmanyan@nczd.ruhttps://orcid.org/0000-0001-6474-6766БакрадзеД.М.BakradzeMaya G.

Москва

Moscow

https://orcid.org/0000-0001-8085-4513ТаточенкоВ. К.TatochenkoVladimir K.

Москва

Moscow

ГадлияД. Д.GadliaDiana D.

Москва

Moscow

Национальный медицинский исследовательский центр здоровья детей; Российский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияNational Medical Research Center of Children’s Health; Pirogov Russian National Research Medical UniversityRussian FederationНациональный медицинский исследовательский центр здоровья детейРоссияNational Medical Research Center of Children’s HealthRussian Federation201727092017164334341Copyright © Полякова А.С., БакрадзеД. М.G., Таточенко В.К., Гадлия Д.Д., 20172017Полякова А.С., БакрадзеД. М., Таточенко В.К., Гадлия Д.Д.Polyakova A.S., Bakradze M.G., Tatochenko V.K., Gadlia D.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1794

С учетом  колоссальной   частоты  инфекционных  заболеваний  среди  детского  населения  перед  педиатрами  стоит задача не просто вылечить пациента,  но сделать  это в максимально короткие сроки с индивидуальным  подходом к каждому  ребенку. Одним из основных аспектов диагностики у лихорадящих детей является  дифференцирование бактериальной инфекции от вирусной с целью назначения своевременной антибактериальной терапии одним пациентам и предупреждения  полипрагмазии  у других. Кроме того, немаловажный  момент заключается в определении категории пациентов с тяжелой  бактериальной  инфекцией, требующей наиболее  пристального  внимания. В статье представлены  основные аспекты  дифференциальной диагностики  бактериальных  и вирусных инфекций  с учетом клинической симптоматики и лабораторных  показателей  — концентрации  прокальцитонина,  С-реактивного белка, лейкоцитов.  Даны пределы  значений прокальцитонина  при различных  нозологических  формах  и возможности  их использования при назначении, продолжении или замене антибактериальной  терапии в педиатрической практике. 

Considering the colossal frequency of infectious diseases among children, pediatricians face the task not only to cure the patient but also to do this as soon as possible with an individual approach to each child. One of the main aspects of diagnosis in febrile children is the differentiation  of a bacterial infection from viral one in order  to assign timely antibiotic therapy to one patient and to prevent excessive assignment to others. In addition, an important point is to identify the category of patients with a severe bacterial infection, which requires  the most  attention.  The article reveals  the main points  of a differential  diagnosis  of bacterial  and viral infections, considering clinical symptoms and laboratory parameters: the concentration of procalcitonin, C-reactive  protein, and leukocytes. The limits of procalcitonin values for various nosological forms and the possibility of their use in terms of the appointment, continuation or replacement of antibacterial therapy in pediatric practice are described.

прокальцитонинС-реактивный белокмаркеры бактериального воспалениялихорадка у детей.procalcitoninC-reactive proteinbacterial inflammation markersfever in childrenАО «Термо Фишер Сайентифик»Support of Thermo Fisher ScientificReferencesNational Institute for Health and Care Excellence: Clinical Guidelines. London, UK: National Institute for Health and Care Excellence; 2003. 310 p.National Institute for Health and Care Excellence: Clinical Guidelines. London, UK: National Institute for Health and Care Excellence; 2003. 310 p.Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадящий ребенок. Протоколы диагностики и лечения. — М.: ПедиатрЪ; 2017. — 320 с. [Baranov AA, Tatochenko VK, Bakradze MD. Likhoradyashchii rebenok. Protokoly diagnostiki i lecheniya. Moscow: Pediatr””; 2017. 320 p. (In Russ).]Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадящий ребенок. Протоколы диагностики и лечения. — М.: ПедиатрЪ; 2017. — 320 с. [Baranov AA, Tatochenko VK, Bakradze MD. Likhoradyashchii rebenok. Protokoly diagnostiki i lecheniya. Moscow: Pediatr””; 2017. 320 p. (In Russ).]Yo CH, Hsieh PS, Lee SH, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta-analysis. Ann Emerg Med. 2012;60(5):591–600. doi: 10.1016/j.annemergmed.2012.05.027.Yo CH, Hsieh PS, Lee SH, et al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis for the detection of serious bacterial infections in children presenting with fever without source: a systematic review and meta-analysis. Ann Emerg Med. 2012;60(5):591–600. doi: 10.1016/j.annemergmed.2012.05.027.Jurado RL. Why shouldn’t we determine the erythrocyte sedimentation rate? Clin Infect Dis. 2001;33(4):548–549. doi: 10.1086/322605.Jurado RL. Why shouldn’t we determine the erythrocyte sedimentation rate? Clin Infect Dis. 2001;33(4):548–549. doi: 10.1086/322605.Kaur K, Mahajan R, Tanwar A. A novel marker procalcitonin may help stem the antibiotic overuse in emergency setting. Int J Appl Basic Med Res. 2013;3(2):77–83. doi: 10.4103/2229-516X.117051.Kaur K, Mahajan R, Tanwar A. A novel marker procalcitonin may help stem the antibiotic overuse in emergency setting. Int J Appl Basic Med Res. 2013;3(2):77–83. doi: 10.4103/2229-516X.117051.Quenot JP, Luyt CE, Roche N, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care. 2013;3(1):21. doi: 10.1186/2110-5820-3-21.Quenot JP, Luyt CE, Roche N, et al. Role of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapy. Ann Intensive Care. 2013;3(1):21. doi: 10.1186/2110-5820-3-21.Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167(1): 93–97. doi: 10.1016/0014-5793(84)80839-X.Le Moullec JM, Jullienne A, Chenais J, et al. The complete sequence of human preprocalcitonin. FEBS Lett. 1984;167(1): 93–97. doi: 10.1016/0014-5793(84)80839-X.Criticare.chat.ru [интернет]. Зубарев А. Прокальцитонин — новый маркер для диагностики тяжелой инфекции (обзор) // Интенсивная терапия. [Zubarev A. Prokal’tsitonin — novyi marker dlya diagnostiki tyazheloi infektsii (obzor). Intensive Care Journal. (In Russ).] [доступ от 01.07.2017]. Доступ по ссылке http://criticare.chat.ru/004.html.Criticare.chat.ru [интернет]. Зубарев А. Прокальцитонин — новый маркер для диагностики тяжелой инфекции (обзор) // Интенсивная терапия. [Zubarev A. Prokal’tsitonin — novyi marker dlya diagnostiki tyazheloi infektsii (obzor). Intensive Care Journal. (In Russ).] [доступ от 01.07.2017]. Доступ по ссылке http://criticare.chat.ru/004.html.Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518. doi: 10.1016/0140-6736(93)90277-N.Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518. doi: 10.1016/0140-6736(93)90277-N.Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–1608. doi: 10.1210/jcem.79.6.7989463.Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab. 1994;79(6):1605–1608. doi: 10.1210/jcem.79.6.7989463.Bohuon C. A brief history of procalcitonin. Intensive Care Med. 2000;26(Suppl 2):S146–S147. doi: 10.1007/BF02900727.Bohuon C. A brief history of procalcitonin. Intensive Care Med. 2000;26(Suppl 2):S146–S147. doi: 10.1007/BF02900727.Yukioka H, Yoshida G, Kurita S, Kato N. Plasma procalcitonin in sepsis and organ failure. Ann Acad Med Singapore. 2001; 30(5):528–531.Yukioka H, Yoshida G, Kurita S, Kato N. Plasma procalcitonin in sepsis and organ failure. Ann Acad Med Singapore. 2001; 30(5):528–531.Oberhoffer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med. 1999;37(3):363–368. doi: 10.1515/CCLM.1999.060.Oberhoffer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med. 1999;37(3):363–368. doi: 10.1515/CCLM.1999.060.Oberhoffer M, Russwurm S, Bredle D, et al. Discriminative power of inflamatory markers for prediction of tumor necrosis factor-alfa and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitary time points. Intensive Care Med. 2000;26(Suppl 2):S170–174. doi: 10.1007/BF02900732.Oberhoffer M, Russwurm S, Bredle D, et al. Discriminative power of inflamatory markers for prediction of tumor necrosis factor-alfa and interleukin-6 in ICU patients with systemic inflammatory response syndrome (SIRS) or sepsis at arbitary time points. Intensive Care Med. 2000;26(Suppl 2):S170–174. doi: 10.1007/BF02900732.Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–5584. doi: 10.1210/en.2003-0854.Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology. 2003;144(12):5578–5584. doi: 10.1210/en.2003-0854.Dubos F, Korezowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med. 2008;162(12): 1157–1163. doi: 10.1001/archpedi.162.12.1157.Dubos F, Korezowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. Arch Pediatr Adolesc Med. 2008;162(12): 1157–1163. doi: 10.1001/archpedi.162.12.1157.Meisner M, Tschaikowsky K, Hutzler A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;24(7):680–684. doi: 10.1007/s001340050644.Meisner M, Tschaikowsky K, Hutzler A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med. 1998;24(7):680–684. doi: 10.1007/s001340050644.Meisner M. PCT, procalcitonin — a new, innovative infection parameter. Berlin: Brahms Diagnostica; 1996. pp. 3–41.Meisner M. PCT, procalcitonin — a new, innovative infection parameter. Berlin: Brahms Diagnostica; 1996. pp. 3–41.Manzano S, Bailey B, Gervaix A, et al. Markers for bacterial infection in children with fever without source. Arch Dis Child. 2011;96(5):440–446. doi: 10.1136/adc.2010.203760.Manzano S, Bailey B, Gervaix A, et al. Markers for bacterial infection in children with fever without source. Arch Dis Child. 2011;96(5):440–446. doi: 10.1136/adc.2010.203760.Mahajan P, Grzybowski M, Chen X, et al. Procalcitonin as a marker of serious bacterial infections in febrile children younger than 3 years old. Acad Emerg Med. 2014;21(2):171–179. doi: 10.1111/acem.12316.Mahajan P, Grzybowski M, Chen X, et al. Procalcitonin as a marker of serious bacterial infections in febrile children younger than 3 years old. Acad Emerg Med. 2014;21(2):171–179. doi: 10.1111/acem.12316.Старовойтова Е.В. Значение уровня прокальцитонина в крови при дифференциальной диагностике бактериальных и вирусных инфекций у лихорадящих детей: Дис. … канд. мед. наук. — М.; 2007. [Starovoitova EV. Znachenie urovnya prokal’tsitonina v krovi pri differentsial’noi diagnostike bakterial’nykh i virusnykh infektsii u likhoradyashchikh detei. [dissertation] Moscow; 2007. (In Russ).]Старовойтова Е.В. Значение уровня прокальцитонина в крови при дифференциальной диагностике бактериальных и вирусных инфекций у лихорадящих детей: Дис. … канд. мед. наук. — М.; 2007. [Starovoitova EV. Znachenie urovnya prokal’tsitonina v krovi pri differentsial’noi diagnostike bakterial’nykh i virusnykh infektsii u likhoradyashchikh detei. [dissertation] Moscow; 2007. (In Russ).]Гадлия Д.Д. Клинико-лабораторная диагностика тяжелых бактериальных инфекций у детей: Автореф. дис. … канд. мед. наук. — М.; 2017. — 24 с. [Gadliya DD. Kliniko-laboratornaya diagnostika tyazhelykh bakterial’nykh infektsii u detei. [dissertation abstract] Moscow; 2017. 24 p. (In Russ).]Гадлия Д.Д. Клинико-лабораторная диагностика тяжелых бактериальных инфекций у детей: Автореф. дис. … канд. мед. наук. — М.; 2017. — 24 с. [Gadliya DD. Kliniko-laboratornaya diagnostika tyazhelykh bakterial’nykh infektsii u detei. [dissertation abstract] Moscow; 2017. 24 p. (In Russ).]Shaikh N, Borrell JL, Evron J, Leeflang MM. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children. Cochrane Database Syst Rev. 2015;1:CD009185. doi: 10.1002/14651858.CD009185.pub2.Shaikh N, Borrell JL, Evron J, Leeflang MM. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for the diagnosis of acute pyelonephritis in children. Cochrane Database Syst Rev. 2015;1:CD009185. doi: 10.1002/14651858.CD009185.pub2.Coulthard MG, Lambert HJ, Keir MJ. Do systemic symptoms predict the risk of kidney scarring after urinary tract infection? Arch Dis Child. 2009;94(4):278–281. doi: 10.1136/adc.2007.132290.Coulthard MG, Lambert HJ, Keir MJ. Do systemic symptoms predict the risk of kidney scarring after urinary tract infection? Arch Dis Child. 2009;94(4):278–281. doi: 10.1136/adc.2007.132290.Бакрадзе М.Д. Новые лечебно-диагностические и организационные технологии ведения детей с острыми лихорадочными заболеваниями: Дис. … докт. мед. наук. — М.; 2009. — 365 с. [Bakradze MD. Novye lechebno-diagnosticheskie i organizatsionnye tekhnologii vedeniya detei s ostrymi likhoradochnymi zabolevaniyami. [dissertation] Moscow; 2009. 365 p. (In Russ).]Бакрадзе М.Д. Новые лечебно-диагностические и организационные технологии ведения детей с острыми лихорадочными заболеваниями: Дис. … докт. мед. наук. — М.; 2009. — 365 с. [Bakradze MD. Novye lechebno-diagnosticheskie i organizatsionnye tekhnologii vedeniya detei s ostrymi likhoradochnymi zabolevaniyami. [dissertation] Moscow; 2009. 365 p. (In Russ).]Bressan S, Gomez B, Mintegi S, et al. Diagnostic performance of the lab-score in predicting severe and invasive bacterial infections in well-appearing young febrile infants. Pediatr Infect Dis J. 2012;31(12):1239–1244. doi: 10.1097/INF.0b013e318266a9aa.Bressan S, Gomez B, Mintegi S, et al. Diagnostic performance of the lab-score in predicting severe and invasive bacterial infections in well-appearing young febrile infants. Pediatr Infect Dis J. 2012;31(12):1239–1244. doi: 10.1097/INF.0b013e318266a9aa.Domingues О, Rojo P, de las Heras S, et al. Clinical presentation and characteristics of pharyngeal adenovirus infections. Pediatr Infect Dis J. 2005;24(8):733–734. doi: 10.1097/01.inf.0000172942.96436.2d.Domingues О, Rojo P, de las Heras S, et al. Clinical presentation and characteristics of pharyngeal adenovirus infections. Pediatr Infect Dis J. 2005;24(8):733–734. doi: 10.1097/01.inf.0000172942.96436.2d.Дарманян А.С. Совершенствование методов диагностики и лечения острых тонзиллитов у детей: Дис. … канд. мед. наук. — M.; 2010. [Darmanyan AS. Sovershenstvovanie metodov diagnostiki i lecheniya ostrykh tonzillitov u detei. [dissertation] Moscow; 2010. (In Russ).]Дарманян А.С. Совершенствование методов диагностики и лечения острых тонзиллитов у детей: Дис. … канд. мед. наук. — M.; 2010. [Darmanyan AS. Sovershenstvovanie metodov diagnostiki i lecheniya ostrykh tonzillitov u detei. [dissertation] Moscow; 2010. (In Russ).]Christensen AM, Thomsen MK, Ovesen T, Klug TE. Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis? Scand J Infect Dis. 2014;46(5): 376–383. doi: 10.3109/00365548.2014.885656.Christensen AM, Thomsen MK, Ovesen T, Klug TE. Are procalcitonin or other infection markers useful in the detection of group A streptococcal acute tonsillitis? Scand J Infect Dis. 2014;46(5): 376–383. doi: 10.3109/00365548.2014.885656.Ismaili-Jaha V, Shala M, Azemi M, et al. Procalcitonin is an important but not conclusive marker of bacterial etiology of acute diarrhea in children younger than 5 years. Original paper. Mater Sociomed. 2014;26(2):76–79.Ismaili-Jaha V, Shala M, Azemi M, et al. Procalcitonin is an important but not conclusive marker of bacterial etiology of acute diarrhea in children younger than 5 years. Original paper. Mater Sociomed. 2014;26(2):76–79.National Collaborating Centre for Women’s and Children’s Health. Diarrhoea and vomiting caused by gastroenteritis — diagnosis, assessment and management in children younger than 5 years. NICE Clinical Guideline. London, UK: RCOG Press; 2009.National Collaborating Centre for Women’s and Children’s Health. Diarrhoea and vomiting caused by gastroenteritis — diagnosis, assessment and management in children younger than 5 years. NICE Clinical Guideline. London, UK: RCOG Press; 2009.Дарманян А.С. Лечение кишечных инфекций у детей // Фарматека. — 2012. — № S3. — С. 34–38. [Darmanyan AS. Lechenie kishechnykh infektsii u detei. Farmateka. 2012;(S3): 34–38. (In Russ).]Дарманян А.С. Лечение кишечных инфекций у детей // Фарматека. — 2012. — № S3. — С. 34–38. [Darmanyan AS. Lechenie kishechnykh infektsii u detei. Farmateka. 2012;(S3): 34–38. (In Russ).]Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132–152. doi: 10.1097/MPG.0000000000000375.Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132–152. doi: 10.1097/MPG.0000000000000375.Liu LJ, Yang YJ, Kuo PH, et al. Diagnostic value of bacterial stool cultures and viral antigen tests based on clinical manifestations of acute gastroenteritis in pediatric patients. Eur J Clin Microbiol Infect Dis. 2005;24(8):559–561. doi: 10.1007/s10096-005-1373-z.Liu LJ, Yang YJ, Kuo PH, et al. Diagnostic value of bacterial stool cultures and viral antigen tests based on clinical manifestations of acute gastroenteritis in pediatric patients. Eur J Clin Microbiol Infect Dis. 2005;24(8):559–561. doi: 10.1007/s10096-005-1373-z.Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. 2008;46(Suppl 2):S81–S122. doi: 10.1097/MPG.0b013e31816f7b16.Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr. 2008;46(Suppl 2):S81–S122. doi: 10.1097/MPG.0b013e31816f7b16.Henry BM, Roy J, Ramakrishnan PK, et al. Procalcitonin as a serum biomarker for differentiation of bacterial meningitis from viral meningitis in children: evidence from a meta-analysis. Clin Pediatr (Phila). 2016;55(8):749–764. doi: 10.1177/0009922815606414.Henry BM, Roy J, Ramakrishnan PK, et al. Procalcitonin as a serum biomarker for differentiation of bacterial meningitis from viral meningitis in children: evidence from a meta-analysis. Clin Pediatr (Phila). 2016;55(8):749–764. doi: 10.1177/0009922815606414.Baraff LJ, Oslund S, Prather M. Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteriemia. Pediatrics. 1993;92(1):140–143.Baraff LJ, Oslund S, Prather M. Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteriemia. Pediatrics. 1993;92(1):140–143.Aabenhus R, Jensen JU. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim Care Respir J. 2011;20(4):360–367. doi: 10.4104/pcrj.2011.00064.Aabenhus R, Jensen JU. Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? Prim Care Respir J. 2011;20(4):360–367. doi: 10.4104/pcrj.2011.00064.Assink-de Jong E, de Lange DW, van Oers JA, et al. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients — calculated sample size: 1816 patients. BMC Infect Dis. 2013;13:178. doi: 10.1186/1471-2334-13-178.Assink-de Jong E, de Lange DW, van Oers JA, et al. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): a randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration in intensive care unit patients — calculated sample size: 1816 patients. BMC Infect Dis. 2013;13:178. doi: 10.1186/1471-2334-13-178.Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066. doi: 10.1001/jama.2009.1297.Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–1066. doi: 10.1001/jama.2009.1297.Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474. doi: 10.1016/S0140-6736(09)61879-1.Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–474. doi: 10.1016/S0140-6736(09)61879-1.Pierce R, Bigham MT, Guliano JS Jr. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr. 2014;26(3):292–298. doi: 10.1097/MOP.0000000000000092.Pierce R, Bigham MT, Guliano JS Jr. Use of procalcitonin for the prediction and treatment of acute bacterial infection in children. Curr Opin Pediatr. 2014;26(3):292–298. doi: 10.1097/MOP.0000000000000092.Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048–2058. doi: 10.1097/CCM.0b013e31821e87918.Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048–2058. doi: 10.1097/CCM.0b013e31821e87918.

The authors declare that there are no conflicts of interest present.